HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1

Hang You,Guojing Song,Zhizhen Xu,Saipeng Chen,Wenhao Shen,Heting Liu,Bingqian Deng,Jun Li,Gang Huang
DOI: https://doi.org/10.1186/s12967-024-04970-w
IF: 8.44
2024-02-18
Journal of Translational Medicine
Abstract:Abstract Background Castration-resistant prostate cancer (CRPC) is refractory to hormone treatment, and the underlying mechanism has not been fully elucidated. This study aimed to clarify the role and mechanism of Human antigen R (HuR) as a therapeutic target for CRPC progression. Methods HuR was knocked out by Cas9 or inhibited by the HuR-specific inhibitor KH-3 in CRPC cell lines and in a mouse xenograft model. The effects of HuR inhibition on tumour cell behaviors and signal transduction were examined by proliferation, transwell, and tumour xenograft assays. Posttranscriptional regulation of BCAT1 by HuR was determined by half-life and RIP assays. Results HuR knockout attenuated the proliferation, migration, and invasion of PC3 and DU145 cells in vitro and inhibited tumour progression in vivo. Moreover, BCAT1 was a direct target gene of HuR and mediated the oncogenic effect of HuR on CRPC. Mechanistically, HuR directly interacted with BCAT1 mRNA and upregulated BCAT1 expression by increasing the stability and translation of BCAT1, which activated ERK5 signalling. Additionally, the HuR-specific inhibitor KH-3 attenuated CRPC progression by disrupting the HuR-BCAT1 interaction. Conclusions We confirmed that the HuR/BCAT1 axis plays a crucial role in CRPC progression and suggest that inhibiting the HuR/BCAT1 axis is a promising therapeutic approach for suppressing CRPC progression. Graphical Abstract
medicine, research & experimental
What problem does this paper attempt to address?
This paper attempts to address the mechanism of Castration - Resistant Prostate Cancer (CRPC) progression, especially the role of HuR (Human antigen R) in CRPC and its potential therapeutic targets. Specifically, the study aims to clarify the role and mechanism of HuR in CRPC progression and explore whether inhibiting HuR can be a new method for treating CRPC. ### Research Background and Problems 1. **Clinical Challenges of CRPC**: - CRPC is the advanced stage of prostate cancer and is insensitive to androgen deprivation therapy (ADT). - Although new hormonal therapy drugs such as abiraterone, enzalutamide and the PARP inhibitor olaparib have improved the prognosis of CRPC, tumors will eventually become resistant to them. - Therefore, there is an urgent need to identify new therapeutic targets and drugs to manage CRPC. 2. **Mechanism of Action of HuR**: - HuR is an RNA - binding protein. It is known to regulate proliferation, apoptosis, senescence, inflammation and immune responses in multiple cancers by interacting with mRNA. - In CRPC, the expression of HuR is up - regulated and may be involved in abnormal amino acid metabolism. - Previous studies have shown that the HuR - specific inhibitor KH - 3 can significantly slow down the progression of breast cancer and pancreatic cancer by blocking the interaction between HuR and mRNA. ### Research Objectives - **Clarify the Role of HuR in CRPC Progression**: By knocking out or inhibiting HuR, study its impact on CRPC cell behavior and signal transduction. - **Identify the Direct Target Genes of HuR**: Through RNA stability analysis and RIP experiments, determine the key genes regulated by HuR at the post - transcriptional level. - **Reveal the HuR Regulatory Mechanism**: Elucidate how HuR affects the ERK5 signaling pathway by regulating specific genes (such as BCAT1), thereby promoting the progression of CRPC. ### Main Findings - **HuR Knockout Inhibits CRPC Progression**: In vitro experiments show that HuR knockout significantly inhibits the proliferation, migration and invasion abilities of PC3 and DU145 cells; in vivo experiments also show that HuR knockout inhibits tumor growth and bone metastasis. - **BCAT1 is a Direct Target Gene of HuR**: Through RNA - seq and RIP experiments, it is confirmed that BCAT1 is an important target gene of HuR. HuR up - regulates BCAT1 expression by stabilizing BCAT1 mRNA and promoting its translation. - **HuR/BCAT1 Axis Activates the ERK5 Signaling Pathway**: The up - regulated BCAT1 promotes the progression of CRPC by activating the GRM1/ERK5 signaling pathway. - **KH - 3 Inhibits the HuR/BCAT1 Interaction**: The HuR - specific inhibitor KH - 3 effectively inhibits the progression of CRPC by disrupting the interaction between HuR and BCAT1 mRNA. ### Conclusion This study is the first to demonstrate the specific mechanism by which HuR promotes CRPC progression by regulating BCAT1 expression, and proposes that inhibiting the HuR/BCAT1 axis may be an effective strategy for treating CRPC. This finding provides a theoretical basis for the development of new CRPC therapeutic targets.